Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Namdong-gu
Clinical trial register · South Korea

Clinical Trials in Namdong-gu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3409 matching records held by the registry are in this view. Synced 17 Nov 2026, 03:18 UTC
3409
Studies in scope
all four open statuses
1874
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Seoul 2866 Daegu 553 Seongnam-si 485 Busan 470 Goyang-si 399

Trials with a site in Namdong-gu

35 of 3409 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Bristol-Myers Squibb
Phase 3
2,380
Namdong-gu, Bucheon-si, Goyang-si, Suwon, Busan, Haeundae-gu, Seoul, Dong-gu, Ulsan
2026-12-16
Not yet open
Eli Lilly and Company
Phase 3
2,115
Ansan-si, Busan, Guri-si, Gwangju, Gyeongsan-si, Junggu, Namdong-gu, Seogu
2026-12
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
Eli Lilly and Company
Phase 2
350
Gangnam-gu, Incheon, Namdong-gu, Seoul
2026-05-20
Recruiting
Regeneron Pharmaceuticals
Phase 2
99
Namdong-gu, Seoul
2026-05-06
Recruiting
Eli Lilly and Company
Phase 3
1,980
Namdong-gu, Seogu, Seongnam, Seoul, Yangsan
2026-02-06
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
450
Goyang-si, Junggu, Namdong-gu, Seongnam, Seoul
2025-12-12
Recruiting
Eli Lilly and Company
Phase 3
7,140
Busan, Daegu, Guri-si, Gwangju, Namdong-gu, Seongnam, Seoul, Ulsan
2025-12-01
Recruiting
Eli Lilly and Company
Phase 3
1,100
Anyang-si, Busan, Cheongju-si, Guri-si, Incheon, Junggu, Namdong-gu, Seogu
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,100
Busan, Cheongju-si, Guri-si, Junggu, Namdong-gu, Seogu, Seongnam, Seoul
2025-10-15
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Daegu, Gwangju, Namdong-gu, Seongnam, Seoul, Suwon, Ulsan
2025-09-02
Recruiting
AstraZeneca
Phase 2
278
Cheongju-si, Namdong-gu, Seongnam-si, Seoul, Suwon
2025-08-07
Recruiting
Pfizer
Phase 3
300
Namdong-gu, Gwangju, Seoul
2025-07-14
Recruiting
Hoffmann-La Roche
Phase 3
80,000
Gwangju, Gyeonggi-do, Incheon, Namdong-gu, Seongnam-si, Seoul, Suwon
2025-07-02
Recruiting
Pfizer
Phase 3
2,330
Donggu, Namdong-gu, Wŏnju, Gwangju, Ansan-si, Suwon, Dongjak-gu, Gangnam-gu
2024-12-08
Active, closed
Eli Lilly and Company
Phase 3
1,400
Busan, Cheongju-si, Gangnam-gu, Gangseo-gu, Gwangju, Incheon, Jeju City, Namdong-gu
2024-10-24
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Cheongju-si, Namdong-gu, Hwasun, Goyang-si, Seongnam-si, Yangsan, Busan, Seoul
2024-10-07
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
AstraZeneca
Phase 2
257
Incheon, Namdong-gu, Seoul
2024-08-22
Recruiting
AstraZeneca
Phase 3
582
Goyang-si, Namdong-gu, Seoul, Suwon
2024-04-29
Active, closed
Eli Lilly and Company
Phase 3
17,300
Bucheon-si, Daegu, Daejeon, Dongjak-gu, Gwangju, Namdong-gu, Seongnam, Seoul
2024-03-05
Active, closed
Eli Lilly and Company
Phase 3
3,127
Namdong-gu, Ansan-si, Anyang-si, Suwon, Busan, Seoul, Seogu
2023-06-05
Active, closed
Merck Sharp & Dohme LLC
Phase 2
129
Namdong-gu, Seoul
2023-03-16
Active, closed
Pfizer
Phase 3
624
Namdong-gu, Goyang-si, Seongnam, Suwon, Seoul
2023-03-03
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
Eli Lilly and Company
Phase 3
1,500
Busan, Guri-si, Gwangju, Incheon, Junggu, Namdong-gu, Seongnam, Seongnam-si
2022-10-10
Active, closed
Pfizer
Phase 3
854
Namdong-gu, Hwasun Gun, Seongnam, Busan, Seoul, Daegu, Junggu
2022-03-25
Active, closed
Eli Lilly and Company
Phase 3
874
Cheonan-si, Namdong-gu, Suwon, Daegu, Busan, Seoul
2021-10-04
Active, closed
Pfizer
Phase 3
77
Namdong-gu, Goyang-si, Seongnam, Seoul
2021-09-29
Active, closed
Loxo Oncology, Inc.
Phase 3
282
Namdong-gu, Seocho-Gu, Seoul, Busan
2021-09-23
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Cheonan-si, Jemulpo-gu, Cheongju-si, Gangwon-do, Gyeonggi-do, Namdong-Gu, Seongbuk-Gu, Seongnam
2021-08-27
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Namdong-gu, Seoul, Busan
2021-04-08
Active, closed
Eli Lilly and Company
Phase 3
5,637
Cheongju-si, Cheonan-si, Incheon, Namdong-gu, Goyang-si, Seongnam, Busan, Haeundae-gu
2017-07-12
Active, closed
Eli Lilly and Company
Phase 3
669
Cheongju-si, Incheon, Namdong-gu, Seongnam, Seoul, Ulsan
2014-07-22
Rows per page Showing 1–35 of 35
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 November 2026. https://priyalifescience.com/clinical-trials-south-korea/city/namdong-gu

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,409 studies in total at the last sync on 17 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 35 of those studies with a site in Namdong-gu.

How many clinical trials are recruiting in Namdong-gu?

18 of the 35 studies on this page are recruiting new participants as of the 17 Nov 2026, 03:18 UTC sync. A further 2 have not yet opened recruitment, 15 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Namdong-gu), 35 studies
PhaseStudiesRecruitingShare
Phase 3291382.9%
Phase 26517.1%

Most active sponsors

Lead sponsors with the most studies (Namdong-gu)
Lead sponsorStudiesRecruiting
Eli Lilly and Company157
Pfizer52
AstraZeneca33
Hoffmann-La Roche32
Loxo Oncology, Inc.30
Bristol-Myers Squibb21
Jazz Pharmaceuticals11
Merck Sharp & Dohme LLC10
Mirati Therapeutics Inc.11
Regeneron Pharmaceuticals11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.